FDA enforcing QbD from 2013 [Dissolution / BCS / IVIVC]

posted by ElMaestro  – Denmark, 2012-01-19 16:19 (5257 d 18:42 ago) – Posting: # 7965
Views: 5,518

Hi all,

I note that FDA has been moving lately in the area of QbD and they seem to be mandating QbD from 2013 for ANDAs / 505(j)'s.
Here's a presentation.

They have even published an example on how it could be done for an MR generic.

I just skimmed through it and I think it is very, very extensive. If this example is in anyway representative of the amount of typically needed from an applicant/developer then I think US development is going to be a lot more expensive in the future.

What's your take on this?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
143 visitors (0 registered, 143 guests [including 18 identified bots]).
Forum time: 12:01 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5